Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Rhea-AI Summary

Renovaro Biosciences Inc. announced the results of the Special Meeting of Shareholders, where all matters put forward were approved. The meeting was held on January 25, 2024, and the results will be available on the Company's Form 8-K filed on EDGAR at www.sec.gov/edgar.

LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.

All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.

For complete results on all matters voted on at the meeting, please consult the Company's Form 8-K which will be filed on EDGAR at www.sec.gov/edgar.

ABOUT THE COMPANY
Renovaro has developed advanced cell, gene, and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, go to their website at www.renovarobio.com.

Contact: ir@renovarobio.com
Source: Renovaro Bioscience Inc.

FAQ

When was the Special Meeting of Shareholders held for Renovaro Biosciences Inc.?

The Special Meeting of Shareholders for Renovaro Biosciences Inc. was held on January 25, 2024.

What was the outcome of the Special Meeting of Shareholders for Renovaro Biosciences Inc.?

All matters put forward were approved at the Special Meeting of Shareholders for Renovaro Biosciences Inc.

Where can I find the complete results of all matters voted on at the meeting for Renovaro Biosciences Inc.?

The complete results will be available on the Company's Form 8-K, which will be filed on EDGAR at www.sec.gov/edgar.